<DOC>
	<DOCNO>NCT02155673</DOCNO>
	<brief_summary>The primary objective study determine safety tolerability extend dose GCS-100 patient CKD .</brief_summary>
	<brief_title>A Phase 2 Extension Study Study GCS-100-CS-4002</brief_title>
	<detailed_description>Galectin-3 contributes fibrosis , elevate patient ESRD , correlate adverse outcome . Animal model genetic knockout galectin-3 demonstrate reduction structural functional deficit kidney . GCS-100 galectin-3 antagonist show reduce fibrosis pre-clinically . Based role galectin-3 fibrosis kidney disease , Sponsor believe GCS-100 may effective treat patient CKD . Study GCS-100-CS-4002 ongoing randomize , placebo control study GCS-100 Stage 3b 4 CKD . The objective study determine safety efficacy 8 weekly injection GCS-100 eGFR . Patients complete study without adverse safety event , may ask participate study test safety prolong administration study drug .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>1 . Subject capable understand purpose risk study able provide write informed consent 2 . Subject enrol complete End Study ( Day 85 ) GCS100CS4002 1 . Subject experience Grade 3 bad adverse event relate GCS100 clinical study GCS100CS4002 2 . Systolic blood pressure ≤90 mmHg ≥160 mmHg diastolic blood pressure ≤40 mmHg ≤100 mmHg screen 3 . Subject clinical laboratory result : 1 . Hemoglobin : ≤9g/dL 2 . Total bilirubin : &gt; 1.5X upper limit normal ( ULN ) 3 . ALT and/or AST : &gt; 2.5X ULN 4 . Subject concomitant disease condition , include laboratory abnormality , , opinion investigator , could interfere conduct study put subject unacceptable risk 5 . Subject may require renal replacement therapy within next 2 month , discretion investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>